Literature DB >> 9732228

Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features.

K Tsugawa1, Y Yonemura, Y Hirono, S Fushida, M Kaji, K Miwa, I Miyazaki, H Yamamoto.   

Abstract

We examined amplification of the c-met, c-erbB-2, and epidermal growth factor receptor (EGFR) gene in the patients with primary gastric cancer, and compared the data with clinical features in order to clarify the relationship between oncogenic abnormality and clinical features. Oncogene amplifications were examined by slot blot hybridization using DNAs extracted from formalin-fixed and paraffin-embedded tissues of primary gastric cancers. Seven of the seventy cancers (10.0%) had c-met gene amplification, nine (12.9%) had c-erbB-2 gene amplification, and six (8.6%) had EGFR gene amplification, respectively. Eighteen cases (25.7%) exhibited one or multiple oncogene amplification, and two cases (2.9%) exhibited simultaneous amplification of the three genes. The cases with c-met gene amplification tend to show invasive character and were related to peritoneal dissemination. The cases with c-erbB-2 gene amplification were related to lymph node metastasis. The cases with EGFR gene amplification had large tumors and were in highly advanced stage. The survival rate in patients with oncogene amplification was significantly lower than that in patients without amplification. Our data indicated that these genes were related to growth and metastasis of gastric cancer. Furthermore, this study about the three genes suggested that the type of activated gene might decide on the type of metastasis and clinical features.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9732228     DOI: 10.1159/000011898

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  42 in total

1.  In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice.

Authors:  C J Bruns; M T Harbison; H Kuniyasu; I Eue; I J Fidler
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

2.  Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.

Authors:  Debora de Melo Gagliato; Denis L Fontes Jardim; Gerald Falchook; Chad Tang; Ralph Zinner; Jennifer J Wheler; Filip Janku; Vivek Subbiah; Sarina A Piha-Paul; Siqing Fu; Kenneth Hess; Sinchita Roy-Chowdhuri; Stacy Moulder; Ana M Gonzalez-Angulo; Funda Meric-Bernstam; David S Hong
Journal:  Clin Breast Cancer       Date:  2014-06-23       Impact factor: 3.225

3.  Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.

Authors:  Nozomu Fuse; Yasutoshi Kuboki; Takeshi Kuwata; Tomohiro Nishina; Shigenori Kadowaki; Eiji Shinozaki; Nozomu Machida; Satoshi Yuki; Akira Ooki; Shinya Kajiura; Tetsuo Kimura; Takeharu Yamanaka; Kohei Shitara; Akiko Kawano Nagatsuma; Takayuki Yoshino; Atsushi Ochiai; Atsushi Ohtsu
Journal:  Gastric Cancer       Date:  2015-02-15       Impact factor: 7.370

4.  Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection.

Authors:  Ho Suk Oh; Dae-Woon Eom; Gil Hyun Kang; Yong Chel Ahn; Sang Jin Lee; Ji-Hoon Kim; Hyuk Jai Jang; Eun Jung Kim; Kwang Hoon Oh; Heui June Ahn
Journal:  Gastric Cancer       Date:  2013-08-17       Impact factor: 7.370

Review 5.  MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.

Authors:  Hisato Kawakami; Isamu Okamoto
Journal:  Gastric Cancer       Date:  2015-12-21       Impact factor: 7.370

6.  c-MET as a potential therapeutic target and biomarker in cancer.

Authors:  J Rafael Sierra; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

7.  Prognostic significance of cyclooxygenase-2, epidermal growth factor receptor 1, and microvascular density in gastric cancer.

Authors:  M S Al-Moundhri; I Al-Hadabi; K Al-Mawaly; S Kumar; F A R Al-Lawati; G Bhatnager; S Kuruvila; A Al-Hamdani; S M El-Sayed; B Al-Bahrani
Journal:  Med Oncol       Date:  2011-11-03       Impact factor: 3.064

Review 8.  Genomic and genetic alterations influence the progression of gastric cancer.

Authors:  Stefania Nobili; Lorenzo Bruno; Ida Landini; Cristina Napoli; Paolo Bechi; Francesco Tonelli; Carlos A Rubio; Enrico Mini; Gabriella Nesi
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

9.  MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer.

Authors:  Yang Yang; Nandie Wu; Jie Shen; Cristina Teixido; Xia Sun; Zihan Lin; Xiaoping Qian; Zhengyun Zou; Wenxian Guan; Lixia Yu; Rafael Rosell; Baorui Liu; Jia Wei
Journal:  Gastric Cancer       Date:  2015-09-24       Impact factor: 7.370

10.  Mouse gastric tumor models with prostaglandin E2 pathway activation show similar gene expression profiles to intestinal-type human gastric cancer.

Authors:  Hiraku Itadani; Hiroko Oshima; Masanobu Oshima; Hidehito Kotani
Journal:  BMC Genomics       Date:  2009-12-17       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.